- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Hispanic Patients With Select Blood Cancers Have Worse Survival Outcomes
June 22nd 2020, 4:01am
Significant differences were seen between Hispanic and non-Hispanic white patients with hematological malignancies in Texas in terms of the age of diagnosis and long-term survival outcomes.
Real-World Data Show Improved Survival With Adjuvant Immunotherapy in Melanoma
June 22nd 2020, 4:01am
The use of adjuvant immunotherapy in patients with resected stage IIIC melanoma resulted in improved survival benefit, according to real-world data from an early analysis of the National Cancer Database.
Early-Onset Cancers Confer a High Risk of Harboring Germline Mutations
June 22nd 2020, 4:01am
Patients 18 to 39 years of age with early-onset cancer had a significantly high risk of harboring germline mutations, suggesting that this population should undergo germline genetic testing, irrespective of tumor type.
iNEST/Atezolizumab Combo Induces Neoantigen-Specific T-Cell Responses in Advanced Solid Tumors
June 22nd 2020, 4:01am
The addition of the individualized neoantigen specific immunotherapy RO7198457 to atezolizumab induced neoantigen-specific T-cell responses, and was found to be well tolerated in patients with advanced solid malignancies.
Lipophilic Statin Use Is Associated With Decreased Mortality in Epithelial Ovarian Cancer
June 22nd 2020, 4:01am
Findings from an observational study of more than 10,000 women with ovarian cancer showed that lipophilic statins were associated with a 43% overall reduction in epithelial ovarian cancer mortality, with declines seen across subtypes.
Isatuximab Triplet Significantly Improves PFS in Relapsed/Refractory Myeloma
June 14th 2020, 7:30pm
European Hematology Association Congress
The triplet therapy of isatuximab-irfc, carfilzomib, and dexamethasone showed a statistically significant improvement in PFS versus carfilzomib and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Mild COVID-19 Symptoms Are Associated with Poorer Outcomes in Sickle Cell Disease
June 14th 2020, 7:14pm
European Hematology Association Congress
Results from a survey of patients in the United Kingdom showed patients with sickle cell disease diagnosed with COVID-19 and who had mild symptoms were more likely to die or require mechanical ventilation than those with more severe symptoms of COVID-19.
Endotheliopathy: A Marker of Progression to Critical Illness in COVID-19
June 14th 2020, 7:11pm
European Hematology Association Congress
Endotheliopathy represents a marker of progression to critical illness in patients with COVID-19 infection and soluble thrombomodulin segregates with mortality.
Ropeginterferon Alfa-2b Helps Maintain Hematocrit Control for Low-Risk Polycythemia Vera
June 14th 2020, 7:00pm
European Hematology Association Congress
More patients with low-risk polycythemia vera treated with ropeginterferon alfa-2b were able to maintain hematocrit levels at or below 45% compared with those who received monthly phlebotomy alone.
Dr. Dimopoulos on the Safety of Zanubrutinib in Waldenström Macroglobulinemia
June 14th 2020, 6:24pm
European Hematology Association Congress
Meletios A. Dimopoulos, MD, discusses safety results from the randomized phase 3 ASPEN trial of zanubrutinib (Brukinsa) in patients with Waldenström macroglobulinemia.
Dr. Talati on Real-World Data With Venetoclax Combinations in AML
June 13th 2020, 9:29pm
European Hematology Association Congress
Chetasi Talati, MD, discusses the ongoing safety analysis of venetoclax (Venclexta)-based combinations in patients with newly diagnosed acute myeloid leukemia.
Eprenetapopt/Azacitidine Shows Encouraging Responses in High-Risk MDS/AML
June 13th 2020, 7:30pm
European Hematology Association Congress
The combination of eprenetapopt and azacitidine led to high objective response rates and complete response rates in patients with TP53-mutated myelodysplastic syndrome and acute myeloid leukemia.
Luspatercept-aamt Reduces RBC Transfusion Burden in Patients With Rare Blood Disorder
June 13th 2020, 6:00pm
European Hematology Association Congress
Data from the BELIEVE trial showed that luspatercept-aamt, a first-in-class erythroid maturation agent designed to regulate late-stage red blood cell maturation, reduced the need for red blood cell transfusions across every subgroup of patients with beta-thalassemia.
Early Data Show CC-93269 has Activity in Multiple Myeloma
June 13th 2020, 6:00pm
European Hematology Association Congress
Interim results from a phase 1 trial show CC-93269 has activity in highly refractory, heavily pretreated patients with multiple myeloma, with an acceptable safety profile.
Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML
June 13th 2020, 5:53pm
European Hematology Association Congress
Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.
Dr. DiNardo on the Results of the VIALE-A Trial in AML
June 13th 2020, 10:00am
European Hematology Association Congress
Courtney DiNardo, MD, MSCE, discusses the results of the phase 3 VIALE-A trial in acute myeloid leukemia (AML).
Adding Subcutaneous Daratumumab to CyBorD Improves Outcomes for AL Amyloidosis
June 13th 2020, 6:30am
European Hematology Association Congress
Subcutaneous daratumumab may be a promising treatment for newly diagnosed patients with light chain amyloidosis who are in urgent need of new treatment options.
Venetoclax/Azacitidine Showcases OS Benefit in Older Patients With AML
June 13th 2020, 6:30am
European Hematology Association Congress
The combination of venetoclax (Venclexta) and azacitidine led to a 34% reduction in the risk of death versus azacitidine alone in treatment-naïve patients with acute myeloid leukemia who are ineligible for intensive therapy.
Narsoplimab Significantly Improves Outcomes in HSCT-TMA
June 12th 2020, 11:14pm
European Hematology Association Congress
Treatment with narsoplimab (OMS721) led to complete responses, improved laboratory markers, and encouraging 100-day survival rates in patients diagnosed with hematopoietic stem cell transplant-thrombotic microangiopathy.
Liso-Cel Induces High Response Rates in High-Risk Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
June 12th 2020, 10:00pm
European Hematology Association Congress
Treatment with the CAR T-cell product lisocabtagene maraleucel led to high response rates, with durable complete responses, in transplant-ineligible patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma who had poor prognostic features.